ACADIA Pharmaceuticals Inc. , a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson’s disease psychosis. It is also developing pimavanserin as a treatment for dementia-related psychosis and as an adjunctive treatment for schizophrenia that are in phase III clinical trials; and pimavanserin as an adjunctive treatment for major depressive disorder. ACADIA Pharmaceuticals Inc. was founded in 1993 and is headquartered in San Diego, California.

  • ACADIA Pharmaceuticals to Present Phase 2 CLARITY Results for Pimavanserin as an Adjunctive Treatment in Major Depressive Disorder at the 2019 American Psychiatric Association Annual Meeting
    on May 18, 2019 at 3:00 pm

    ACADIA Pharmaceuticals Inc. , a biopharmaceutical company focused on the development and commercialization of innovative medicines to address unmet medical needs in central nervous system disorders, today announced it will present data from its Phase 2 CLARITY study, which evaluated the efficacy, safety, and tolerability of pimavanserin as an adjunctive treatment for major depressive disorder at the ... […]

  • Edited Transcript of ACAD earnings conference call or presentation 1-May-19 8:30pm GMT
    on May 9, 2019 at 7:57 am

    Q1 2019 ACADIA Pharmaceuticals Inc Earnings Ca […]

  • Why Acadia Pharmaceuticals Stock Slumped in April
    on May 8, 2019 at 7:30 pm

    The contentious drug-pricing debate weighed on Acadia Pharmaceuticals' shares last month. […]

  • ACADIA Pharmaceuticals to Present at the Bank of America Merrill Lynch Health Care Conference 2019
    on May 7, 2019 at 1:00 pm

    ACADIA Pharmaceuticals Inc. , a biopharmaceutical company focused on the development and commercialization of innovative medicines that address unmet medical needs in central nervous system disorders, today announced that it will present at the Bank of America Merrill Lynch Health Care Conference 2019 on Tuesday, May 14, 2019 at 10:40 a.m. […]

  • See what the IHS Markit Score report has to say about ACADIA Pharmaceuticals Inc.
    on May 7, 2019 at 12:05 pm

    ACADIA Pharmaceuticals Inc NASDAQ/NGS:ACADView full report here! Summary * ETFs holding this stock are seeing positive inflows * Bearish sentiment is moderate * Economic output in this company's sector is expanding Bearish sentimentShort interest | PositiveShort interest is moderate for ACAD with between 5 and 10% of shares outstanding currently on loan. The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Money flowETF/Index ownership | PositiveETF activity is positive. Over the last month, ETFs holding ACAD are favorable, with net inflows of $2.89 billion. Additionally, the rate of inflows is increasing. Economic sentimentPMI by IHS Markit | PositiveAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is strong relative to the trend shown over the past year, and is accelerating. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to score@ihsmarkit.com.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report. […]

  • Acadia Pharmaceuticals (ACAD) Q1 2019 Earnings Call Transcript
    on May 2, 2019 at 7:24 am

    ACAD earnings call for the period ending March 31, 2019. […]

  • Acadia Pharmaceuticals (ACAD) Reports Q1 Loss, Tops Revenue Estimates
    on May 1, 2019 at 11:35 pm

    Acadia (ACAD) delivered earnings and revenue surprises of -9.26% and 6.17%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock? […]

  • Acadia: 1Q Earnings Snapshot
    on May 1, 2019 at 10:29 pm

    On a per-share basis, the San Diego-based company said it had a loss of 59 cents. The results missed Wall Street expectations. The average estimate of five analysts surveyed by Zacks Investment Research ... […]

  • ACADIA Pharmaceuticals Reports First Quarter 2019 Financial Results
    on May 1, 2019 at 8:05 pm

    - 1Q19 Net Sales Grew to $63.0 Million, a 29% Increase Over 1Q18- Updated 2019 Net Sales Guidance to $280 Million to $300 Million- Completed Enrollment in Two Late-Stage Adjunctiv […]

  • Were Hedge Funds Right About Flocking Into ACADIA Pharmaceuticals Inc. (ACAD)?
    on April 30, 2019 at 1:58 am

    Is ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) a good investment right now? We check hedge fund and billionaire investor sentiment before delving into hours of research. Hedge funds spend millions of dollars on Ivy League graduates, expert networks, and get tips from investment bankers and industry insiders. Sure they sometimes fail miserably but historically their consensus stock […]

2 hours ago

Alignmt LLC

No business plan can succeed with a flawed business model. buff.ly/2qhTkRY

#alignmentmap #corporatefinance #keyperformanceindicators #mergersandacquisitions #investorrelations
... See MoreSee Less

View on Facebook

2 hours ago

Alignmt LLC

It’s an exercise, which means it takes repetition. The more you try it, the better you get at it. The more skilled you become seeing things for what they are, the more perception will work for you rather than against you. buff.ly/2qhTkRY

#alignmentmap
... See MoreSee Less

View on Facebook

17 hours ago

Alignmt LLC

Organizing your business will help optimize efficiency in all functional areas, including business development, finance, operations, human resources, legal, IT and more. buff.ly/2qhTkRY

#alignmentmap #corporatefinance #keyperformanceindicators #mergersandacquisitions #investorrelations
... See MoreSee Less

View on Facebook

23 hours ago

Alignmt LLC

"Don't get so hung up on revenue." True story, a client actually said this to me once. I asked: "Do you say the same thing to investors?" There is no better money than revenue and it takes disciplined financial management to make the most of it. buff.ly/2qhTkRY

#alignmentmap #corporatefinance #mergersandacquisitions #investorrelations
... See MoreSee Less

View on Facebook

5 days ago

Alignmt LLC

Every company needs disciplined financial management to ensure its long-term viability in every respect. How precisely are you tracking key performance indicators? buff.ly/2AnLw8v

#keyperformanceindicators #alignmentmap #mergersandacquisitions
... See MoreSee Less

View on Facebook

5 days ago

Alignmt LLC

Who knew finance was so critical to success? buff.ly/2AnLw8v

#keyperformanceindicator #alignmentmap
... See MoreSee Less

View on Facebook

5 days ago

Alignmt LLC

Many companies lack the requisite Corporate finance expertise in-house to achieve important goals, while outsourcing often enables them to reach the next level of productivity In a cost effective, low risk manner.

#mergersandacquisitions #alignmentmap
... See MoreSee Less

View on Facebook
Load More...

FULL NAME*

What's Your Role?*

WORK EMAIL*

COMPANY NAME*

Company Description*

HOW'D YOU HEAR ABOUT US?

DETAILS ABOUT YOUR GOALS

ACADIA Pharmaceuticals Inc.

3611 Valley Centre Drive
Suite 300
San Diego, CA 92130

+1 (858) 558-2871

www.acadia-pharm.com

May 2019
S M T W T F S
« Apr    
 1234
567891011
12131415161718
19202122232425
262728293031  

©2019 ALIGNMT LLC | Alignment Consulting | Mergers & Acquisitions | Investor Relations

CONTACT US

We're not around right now. But you can send us an email and we'll get back to you, asap.

Sending

Log in with your credentials

or    

Forgot your details?

Create Account